AGAlejandro Galindo-Tovar

Alejandro Galindo-Tovar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alejandro Galindo-Tovar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Phosphodiesterase PDE2 activity, increased by isoprenaline, does not reduce β-adrenoceptor-mediated chronotropic and inotropic effects in rat heart

    by Alejandro Galindo-Tovar, María Luisa Vargas, Alberto J. Kaumann

    Myocardial PDE2 activity increases in terminal human heart failure and after isoprenaline infusion in rat heart. PDE2 inhibitors do not potentiate the murine sinoatrial tachycardia produced by noradrenaline. We investigated whether isoprenaline infusion induces PDE2 to decrease the chronotropic and inotropic effects of catecholamines in rat heart. Sprague-Dawley rats were infused with isoprenaline (2.4 mg kg−1 day−1) for 3 days. We used spontaneously beating right atria, paced right ventricular strips and left ventricular papillary muscles. The effects of the PDE2 inhibitors EHNA (10 μM) and Bay 60-7550 (0.1–1 μM) were investigated on the cardiostimulation produced by noradrenaline (ICI118551 50 nM present to block β2-adrenoceptors) and adrenaline (CGP20712A 300 nM present to block β1-adrenoceptors). Hydrolysis of cAMP by PDE2 was measured by radioenzyme assay. Bay 60-7550 but not EHNA increased sinoatrial beating. A stable tachycardia elicited by noradrenaline (10 nM) or adrenaline (1 μM) was not increased by the PDE2 inhibitors. Isoprenaline infusion increased the hydrolytic PDE2 activity threefold in left ventricle, reduced the chronotropic and inotropic effects and potency of noradrenaline and abolished the effects of adrenaline. The potency of the catecholamines was not increased by the PDE2 inhibitors. Neither EHNA nor Bay 60-7550 potentiated the effects of the catecholamines. Rat PDE2 decreased basal sinoatrial beating but did not reduce the sinoatrial tachycardia or increases of ventricular force mediated through β1- and β2-adrenoceptors. The β-adrenoceptor desensitization induced by the isoprenaline infusion was not reversed by the PDE2 inhibitors despite the increased hydrolysis of cAMP by PDE2.


  • Inhibitors of phosphodiesterases PDE2, PDE3, and PDE4 do not increase the sinoatrial tachycardia of noradrenaline and prostaglandin PGE1 in mice

    by Alejandro Galindo-Tovar, María Luisa Vargas, Alberto J. Kaumann

    Phosphodiesterases PDE2, PDE3, and PDE4 are expressed in murine sinoatrial cells. PDE3 and/or PDE4 reduce heart rate but apparently do not influence the tachycardia mediated through sinoatrial β1- and β2-adrenoceptors despite the high content of sinoatrial cAMP. The function of PDE2 is, however, uncertain. Prostaglandin PGE1 elicits sinoatrial tachycardia through EP receptors, but the control by phosphodiesterases is unknown. We investigated on spontaneously beating right atria of mice the effects of the PDE2 inhibitors Bay 60-7550 and EHNA on basal beating and the tachycardia produced by noradrenaline (3 nM) and PGE1 (1 μM). Bay 60-7550 (1 μM), but not EHNA (10 μM), increased basal sinoatrial beating. EHNA also failed to produce tachycardia in the presence of the adenosine deaminase inhibitor 2′-deoxycoformycin (10 μM), remaining inconclusive whether PDE2 reduces basal sinoatrial beating. Rolipram (10 μM) and cilostamide (300 nM) caused moderate tachycardia. The tachycardia evoked by Bay 60-7550 was similar in the absence and presence of rolipram. Noradrenaline elicited stable tachycardia that was not increased by Bay 60-7550. A stable tachycardia caused by PGE1 was not increased by the inhibitors of PDE2, PDE3, and PDE4. Unlike PDE3 and PDE4 which reduce murine basal sinoatrial beating, a possible effect of PDE2 needs further research. The stable tachycardia produced by noradrenaline and PGE1, together with the lack potentiation by the inhibitors of PDE2, PDE3, and PDE4, suggests that cAMP generated at the receptor compartments is hardly hydrolyzed by these phophodiesterases. Evidence from human volunteers is consistent with this proposal.


  • Carvedilol induces greater control of β2- than β1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium

    by Peter Molenaar, Torsten Christ, Emanuel Berk, Andreas Engel, Katherine T. Gillette, Alejandro Galindo-Tovar, Ursula Ravens, Alberto J. Kaumann

    The β-blockers carvedilol and metoprolol provide important therapeutic strategies for heart failure treatment. Therapy with metoprolol facilitates the control by phosphodiesterase PDE3, but not PDE4, of inotropic effects of catecholamines in human failing ventricle. However, it is not known whether carvedilol has the same effect. We investigated whether the PDE3-selective inhibitor cilostamide (0.3 μM) or PDE4-selective inhibitor rolipram (1 μM) modified the positive inotropic and lusitropic effects of catecholamines in ventricular myocardium of heart failure patients treated with carvedilol. Right ventricular trabeculae from explanted hearts of nine carvedilol-treated patients with terminal heart failure were paced to contract at 1 Hz. The effects of (-)-noradrenaline, mediated through β1-adrenoceptors (β2-adrenoceptors blocked with ICI118551), and (-)-adrenaline, mediated through β2-adrenoceptors (β1-adrenoceptors blocked with CGP20712A), were assessed in the absence and presence of the PDE inhibitors. The inotropic potency, estimated from –logEC50s, was unchanged for (-)-noradrenaline but decreased 16-fold for (-)-adrenaline in carvedilol-treated compared to non-β-blocker-treated patients, consistent with the previously reported β2-adrenoceptor-selectivity of carvedilol. Cilostamide caused 2- to 3-fold and 10- to 35-fold potentiations of the inotropic and lusitropic effects of (-)-noradrenaline and (-)-adrenaline, respectively, in trabeculae from carvedilol-treated patients. Rolipram did not affect the inotropic and lusitropic potencies of (-)-noradrenaline or (-)-adrenaline. Treatment of heart failure patients with carvedilol induces PDE3 to selectively control the positive inotropic and lusitropic effects mediated through ventricular β2-adrenoceptors compared to β1-adrenoceptors. The β2-adrenoceptor-selectivity of carvedilol may provide protection against β2-adrenoceptor-mediated ventricular overstimulation in PDE3 inhibitor-treated patients. PDE4 does not control β1- and β2-adrenoceptor-mediated inotropic and lusitropic effects in carvedilol-treated patients.


  • Open Access

    PDE3, but not PDE4, reduces β1‐ and β2‐adrenoceptor‐mediated inotropic and lusitropic effects in failing ventricle from metoprolol‐treated patients

    by Peter Molenaar, Torsten Christ, Rizwan I Hussain, Andreas Engel, Emanuel Berk, Katherine T Gillette, Lu Chen, Alejandro Galindo‐Tovar, Kurt A Krobert, Ursula Ravens, et al.

    Background and Purpose: PDE3 and/or PDE4 control ventricular effects of catecholamines in several species but their relative effects in failing human ventricle are unknown. We investigated whether the PDE3‐selective inhibitor cilostamide (0.3–1 μM) or PDE4 inhibitor rolipram (1–10 μM) modified the positive inotropic and lusitropic effects of catecholamines in human failing myocardium.Experimental Approach: Right and left ventricular trabeculae from freshly explanted hearts of 5 non‐β‐blocker‐treated and 15 metoprolol‐treated patients with terminal heart failure were paced to contract at 1 Hz. The effects of (‐)‐noradrenaline, mediated through β1 adrenoceptors (β2 adrenoceptors blocked with ICI118551), and (‐)‐adrenaline, mediated through β2 adrenoceptors (β1 adrenoceptors blocked with CGP20712A), were assessed in the absence and presence of PDE inhibitors. Catecholamine potencies were estimated from –logEC50s.Key Results: Cilostamide did not significantly potentiate the inotropic effects of the catecholamines in non‐β‐blocker‐treated patients. Cilostamide caused greater potentiation (P = 0.037) of the positive inotropic effects of (‐)‐adrenaline (0.78 ± 0.12 log units) than (‐)‐noradrenaline (0.47 ± 0.12 log units) in metoprolol‐treated patients. Lusitropic effects of the catecholamines were also potentiated by cilostamide. Rolipram did not affect the inotropic and lusitropic potencies of (‐)‐noradrenaline or (‐)‐adrenaline on right and left ventricular trabeculae from metoprolol‐treated patients.Conclusions and Implications: Metoprolol induces a control by PDE3 of ventricular effects mediated through both β1 and β2 adrenoceptors, thereby further reducing sympathetic cardiostimulation in patients with terminal heart failure. Concurrent therapy with a PDE3 blocker and metoprolol could conceivably facilitate cardiostimulation evoked by adrenaline through β2 adrenoceptors. PDE4 does not appear to reduce inotropic and lusitropic effects of catecholamines in failing human ventricle.Linked Article: This article is commented on by Eschenhagen, pp 524–527 of this issue. To view this commentary visit http://dx.doi.org/10.1111/bph.12168


  • Phosphodiesterases do not limit β1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1–5 in rats

    by Alberto J. Kaumann, Alejandro Galindo-Tovar, Elisa Escudero, María Luisa Vargas

    The mammalian heart expresses at least five phosphodiesterases (PDE1–5). Catecholamines produce surges of inotropically relevant cAMP through β1-adrenoceptor stimulation. cAMP is mainly hydrolysed by PDE3 and/or PDE4 thereby blunting contractility. Basal sinoatrial beating rate in mouse, rat, piglet and rabbit sinoatrial cells is reduced by PDE3 and/or PDE4 through hydrolysis of cAMP. However, in rodents, the tachycardia elicited by catecholamines through production of cAMP by β-adrenoceptor activation is not controlled by PDE3 and PDE4, despite a blunting effect of PDE3 or/and PDE4 on basal sinoatrial beating, but it is unknown whether PDE3 limits catecholamine-evoked tachycardia in the rabbit. Since rabbit sinoatrial cells are an important model for pacemaker research, we investigated whether the positive chronotropic effects of (−)-noradrenaline on spontaneously beating right atria of the rabbit are potentiated by inhibition of PDE3 with cilostamide (300 nM). We also studied the sinoatrial effects of the PDE4 inhibitor rolipram (10 μM) and its influence on the responses to (−)-noradrenaline. For comparison, we investigated the influence of cilostamide and rolipram on the positive inotropic responses to (−)-noradrenaline on rabbit left atria and right ventricular papillary muscles. Cilostamide and concurrent cilostamide + rolipram, but not rolipram alone, increased sinoatrial rate by 15% and 31% of the effect of (−)-isoprenaline (200 µM) but the PDE inhibitors did not significantly change the chronotropic potency of (−)-noradrenaline. In contrast in papillary muscle, the positive inotropic effects of (−)-noradrenaline were potentiated 2.4-, 2.6- and 44-fold by cilostamide, rolipram and concurrent cilostamide + rolipram, respectively. In left atrium, the positive inotropic effects of (−)-noradrenaline were marginally potentiated by cilostamide, as well as potentiated 2.7- and 32-fold by rolipram and by concurrent cilostamide and rolipram respectively. To compare the influence of PDE1–5 on basal sinoatrial rate and (−)-noradrenaline-evoked tachycardia, we investigated on rat right atria the effects of selective inhibitors. The PDE4 inhibitor rolipram and non-selective inhibitor isobutyl-methylxanthine caused tachycardia with –logEC50s of 7.2 and 5.0 and E max of 18% and 102% of (−)-isoprenaline, respectively. Rolipram did not change the chronotropic potency of (−)-noradrenaline. At high concentrations (10–30 µM), the PDE1, PDE3 and PDE5 inhibitors 8-methoxymethyl-3-isobutyl-1-methylxanthine, cilostamide and sildenafil, respectively, caused marginal tachycardia but did not significantly change the chronotropic potency of (−)-noradrenaline. The PDE2-selective inhibitor erythro-9-[2-hydroxy-3-nonyl]adenine caused marginal bradycardia at 30 µM and tended to reduce the chronotropic potency of (−)-noradrenaline. Rabbit PDE3 reduces basal sinoatrial rate. Although PDE4 only marginally reduces rate, under conditions of PDE3 inhibition, it further reduces sinoatrial rate. Both PDE3 and PDE4 control atrial and ventricular positive inotropic effects of (−)-noradrenaline. In contrast, neither PDE3 nor PDE4 limit the sinoatrial tachycardia induced by (−)-noradrenaline. In the rat, only PDE4, but not PDE1, PDE2, PDE3 and PDE5, reduces basal sinoatrial rate. None of the five rat PDEs limits the (−)-noradrenaline-evoked tachycardia. Taken together, these results confirm and expand evidence for our proposal that the cAMP-compartment modulating basal sinoatrial rate, controlled by PDE3 and/or PDE4, is different from the PDE-resistant cAMP compartment involved in β1-adrenoceptor-mediated sinoatrial tachycardia.


  • Open Access

    Inotropy and L‐type Ca2+current, activated by β1‐ and β2‐adrenoceptors, are differently controlled by phosphodiesterases 3 and 4 in rat heart

    by Torsten Christ, Alejandro Galindo‐Tovar, Marcus Thoms, Ursula Ravens, Alberto J. Kaumann

    Background and purpose: β1‐ and β2‐adrenoceptors coexist in rat heart but β2‐adrenoceptor‐mediated inotropic effects are hardly detectable, possibly due to phosphodiesterase (PDE) activity. We investigated the influence of the PDE3 inhibitor cilostamide (300 nmol·L−1) and the PDE4 inhibitor rolipram (1 µmol·L−1) on the effects of (−)‐catecholamines.Experimental approach: Cardiostimulation evoked by (−)‐noradrenaline (ICI118551 present) and (−)‐adrenaline (CGP20712A present) through β1‐ and β2‐adrenoceptors, respectively, was compared on sinoatrial beating rate, left atrial and ventricular contractile force in isolated tissues from Wistar rats. L‐type Ca2+‐current (ICa‐L) was assessed with whole‐cell patch clamp.Key results: Rolipram caused sinoatrial tachycardia. Cilostamide and rolipram did not enhance chronotropic potencies of (−)‐noradrenaline and (−)‐adrenaline. Rolipram but not cilostamide potentiated atrial and ventricular inotropic effects of (−)‐noradrenaline. Cilostamide potentiated the ventricular effects of (−)‐adrenaline but not of (−)‐noradrenaline. Concurrent cilostamide + rolipram uncovered left atrial effects of (−)‐adrenaline. Both rolipram and cilostamide augmented the (−)‐noradrenaline (1 µmol·L−1) evoked increase in ICa‐L. (−)‐Adrenaline (10 µmol·L−1) increased ICa‐Lonly in the presence of cilostamide but not rolipram.Conclusions and implications: PDE4 blunts the β1‐adrenoceptor‐mediated inotropic effects. PDE4 reduces basal sinoatrial rate in a compartment distinct from compartments controlled by β1‐ and β2‐adrenoceptors. PDE3 and PDE4 jointly prevent left atrial β2‐adrenoceptor‐mediated inotropy. Both PDE3 and PDE4 reduce ICa‐Lresponses through β1‐adrenoceptors but the PDE3 component is unrelated to inotropy. PDE3 blunts both ventricular inotropic and ICa‐Lresponses through β2‐adrenoceptors.


  • Phosphodiesterases PDE3 and PDE4 jointly control the inotropic effects but not chronotropic effects of (−)-CGP12177 despite PDE4-evoked sinoatrial bradycardia in rat atrium

    by Alejandro Galindo-Tovar, Maria Luisa Vargas, Alberto J. Kaumann

    Acting through a low-affinity site of the β1-adrenoceptor (β1LAR), CGP12177 causes sinoatrial tachycardia and positive inotropic effects in left atrium but not in the ventricle of the rat. However, inhibition of either PDE3 or PDE4 also uncovers positive inotropic effects of CGP12177 in ventricle, but whether these phosphodiesterases also control the atrial agonist effects of CGP12177 was unknown. We, therefore, investigated the effects of the PDE3-selective inhibitor cilostamide (300 nM) and PDE4 inhibitor rolipram (1 µM) on the (−)-CGP12177-evoked increases of sinoatrial beating rate and force of paced left atria of the rat. Rolipram (n = 8) increased basal sinoatrial rate by 27 ± 5 bpm but cilostamide (n = 8) had no effect. The chronotropic potency of (−)-CGP12177 (−logEC50M = 7.5) was not changed by rolipram and cilostamide or their combination. (-)-CGP12177 increased left atrial force with intrinsic activity 0.25 compared to (-)-isoprenaline. Rolipram (n = 8) and cilostamide (n = 8) did not change basal force of left atria but concurrent rolipram + cilostamide (n = 8) increased force by 52 ± 9% of the effect of 200 µM (−)-isoprenaline. Neither rolipram nor cilostamide affected the inotropic potency of (−)-CGP12177 (−logEC50M = 7.4) but concurrent rolipram + cilostamide caused potentiation (−logEC50M = 8.2) and converted (-)-CGP12177 into a full agonist compared to (-)-isoprenaline. Cyclic AMP appears to maintain sinoatrial rate and PDE4 elicits bradycardia through hydrolysis of cAMP in a compartment distinct from the β1LAR-induced cAMP compartment through which (−)-CGP12177 causes tachycardia. In contrast to the (−)-CGP12177-evoked tachycardia, not controlled by PDE3 and PDE4, these isoenzymes jointly reduce (−)-CGP12177-evoked increases of left atrial contractility through β1LAR.


  • Phosphodiesterase‐4 blunts inotropism and arrhythmias but not sinoatrial tachycardia of (−)‐adrenaline mediated through mouse cardiac β 1 ‐adrenoceptors

    by A Galindo‐Tovar, A J Kaumann

    Background and purpose: β 1 and β 2 ‐adrenoceptors coexist in murine heart but β 2 ‐adrenoceptor‐mediated effects have not been detected in atrial and ventricular tissues, possibly due to marked phosphodiesterase (PDE) activity. We investigated the influence of the PDE3 inhibitor cilostamide and PDE4 inhibitor rolipram on the effects of (−)‐adrenaline in three regions of murine heart. Experimental approach: (−)‐Adrenaline‐evoked cardiostimulation was compared on sinoatrial beating rate, left atrial and right ventricular contractile force in isolated tissues from 129SvxC57B1/6 cross mice. Ventricular arrhythmic contractions were also assessed. Key results: Both rolipram (1 μ M ) and cilostamide (300 n M ) caused transient sinoatrial tachycardia but neither enhanced the chronotropic potency of (−)‐adrenaline. Rolipram potentiated 19‐fold (left atrium) and 7‐fold (right ventricle) the inotropic effects of (−)‐adrenaline. (−)‐Adrenaline elicited concentration‐dependent ventricular arrhythmias that were potentiated by rolipram. All effects of (−)‐adrenaline were antagonized by the β 1 ‐adrenoceptor‐selective antagonist CGP20712A (300 n M ). Cilostamide (300 n M ) did not increase the chronotropic and inotropic potencies of (−)‐adrenaline, but administered jointly with rolipram in the presence of CGP20712A, uncovered left atrial inotropic effects of (−)‐adrenaline that were prevented by the β 2 ‐adrenoceptor‐selective antagonist ICI118551. Conclusions and implications: PDE4 blunts the β 1 ‐adrenoceptor‐mediated effects of (−)‐adrenaline in left atrium and right ventricle but not in sinoatrial node. Both PDE3 and PDE4 reduce basal sinoatrial rate in a compartment distinct from the β 1 ‐adrenoceptor compartment. PDE3 and PDE4, acting in concert, prevent left atrial β 2 ‐adrenoceptor‐mediated inotropy. PDE4 partially protects the right ventricle against (−)‐adrenaline‐evoked arrhythmias. British Journal of Pharmacology (2008) 153 , 710–720; doi: 10.1038/sj.bjp.0707631 ; published online 17 December 2007